Akorn PE Ratio 2006-2019 | AKRX

Current and historical p/e ratio for Akorn (AKRX) from 2006 to 2019. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Akorn PE ratio as of August 20, 2019 is 0.00.
Akorn PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2019-08-20 2.78 0.00
2019-06-30 5.15 $-3.81 0.00
2019-03-31 3.52 $-3.62 0.00
2018-12-31 3.39 $-2.97 0.00
2018-09-30 12.98 $-1.26 0.00
2018-06-30 16.59 $-0.70 0.00
2018-03-31 18.71 $0.02 935.50
2017-12-31 32.23 $0.35 92.09
2017-09-30 33.19 $0.61 54.41
2017-06-30 33.54 $0.99 33.88
2017-03-31 24.08 $1.47 16.38
2016-12-31 21.83 $1.48 14.75
2016-09-30 27.26 $1.49 18.30
2016-06-30 28.49 $1.50 18.99
2016-03-31 23.53 $1.27 18.53
2015-12-31 37.31 $1.24 30.09
2015-09-30 28.51 $1.26 22.62
2015-06-30 43.66 $0.76 57.45
2015-03-31 47.51 $0.56 84.84
2014-12-31 36.20 $0.33 109.70
2014-09-30 36.27 $0.18 201.50
2014-06-30 33.25 $0.40 83.13
2014-03-31 22.00 $0.44 50.00
2013-12-31 24.62 $0.46 53.52
2013-09-30 19.68 $0.40 49.20
2013-06-30 13.52 $0.41 32.98
2013-03-31 13.83 $0.40 34.58
2012-12-31 13.36 $0.38 35.16
2012-09-30 13.22 $0.35 37.77
2012-06-30 15.77 $0.36 43.81
2012-03-31 11.70 $0.43 27.21
2011-12-31 11.12 $0.41 27.12
2011-09-30 7.80 $0.59 13.22
2011-06-30 7.00 $0.50 14.00
2011-03-31 5.77 $0.23 25.09
2010-12-31 6.07 $0.21 28.90
2010-09-30 4.04 $-0.05 0.00
2010-06-30 2.97 $-0.15 0.00
2010-03-31 1.53 $-0.13 0.00
2009-12-31 1.79 $-0.29 0.00
2009-09-30 1.37 $-0.28 0.00
2009-06-30 1.21 $-0.19 0.00
2009-03-31 0.86 $-0.14 0.00
2008-12-31 2.30 $-0.08 0.00
2008-09-30 5.13 $-0.12 0.00
2008-06-30 3.31 $-0.20 0.00
2008-03-31 4.73 $-0.22 0.00
2007-12-31 7.34 $-0.22 0.00
2007-09-30 7.49 $-0.23 0.00
2007-06-30 6.99 $-0.20 0.00
2007-03-31 6.75 $-0.18 0.00
2006-12-31 6.25 $-0.08 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.341B $0.694B
Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. They specialize in difficult-to-manufacture sterile and non-sterile dosage forms including: ophthalmics, injectables, oral liquids, otics, topicals, inhalants, and nasal sprays. Akorn markets its products to retail pharmacies, ophthalmologists, optometrists, physicians, veterinarians, hospitals, clinics, wholesalers, distributors, group purchasing organizations, and government agencies. Their strategy is focused on continuing to strengthen our leadership position in the development and marketing of specialized generic and branded pharmaceuticals, over-the-counter (`OTC`) drug products and animal health products.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $51.911B 9.47
Mylan (MYL) United Kingdom $9.559B 4.21
Bausch Health Cos (BHC) Canada $7.495B 5.00
Teva Pharmaceutical Industries (TEVA) Israel $6.999B 2.75
Dr Reddy's Laboratories (RDY) India $5.851B 19.69
ASPEN PHARMACR (APNHY) South Africa $2.022B 0.00
Supernus Pharmaceuticals (SUPN) United States $1.422B 13.90
Amphastar Pharmaceuticals (AMPH) United States $1.010B 49.72
Voyager Therapeutics (VYGR) United States $0.791B 0.00
Homology Medicines (FIXX) United States $0.738B 0.00
CymaBay Therapeutics (CBAY) United States $0.400B 0.00
Mallinckrodt Public Limited Company (MNK) United Kingdom $0.343B 0.47
Assembly Biosciences (ASMB) United States $0.321B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.320B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.260B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.178B 0.00
Sol-Gel Technologies (SLGL) Israel $0.161B 0.00
Aquinox Pharmaceuticals (NLTX) Canada $0.093B 0.00
Teligent (TLGT) United States $0.037B 0.00
China Pharma Holdings (CPHI) China $0.011B 0.00